References
- Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798–811. doi:10.1093/oxfordjournals.aje.a113052.
- Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health. 1997;87(12):1944–50. doi:10.2105/AJPH.87.12.1944.
- Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181(3):831–37. doi:10.1086/315320.
- Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40. doi:10.1001/jama.292.11.1333.
- World Health Organisation. Influenza, Fact sheet on the Internet. Influenza (seasonal), Geneva; 2018 November [accessed 2020 Jan 14]. https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
- European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. [accessed 2020 Jan 14]. https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet.
- Irwin DE, Weatherby LB, Wen-Yi H, Rosenberg DM, Cook SF, Walker AM. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res. 2001;1:8. doi:10.1186/1472-6963-1-8.
- Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiol Infect. 2005;133(2):255–62. doi:10.1017/S0950268804003231.
- Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med. 1982;142:85–89. doi:10.1001/archinte.1982.00340140087016.
- Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, Nichol KL. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35:370–77. doi:10.1086/341403.
- Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer. 2007;109:2357–64. doi:10.1002/cncr.22670.
- Schooling CM, Wong LC, Chau J, Cheung A, Ho A, McGhee SM. Cost-effectiveness of influenza vaccination for elderly people living in the community. Hong Kong Med J. 2009;15(Suppl. 6):44–47.
- Lin HH, Hsu KL, Ko WW, Yang YC, Chang YW, Yu MC, Chen KT. Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. Clin Microbiol Infect. 2010;16:663–70. doi:10.1111/j.1469-0691.2009.02937.x.
- Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive. Aust N Z J Public Health. 2011 Apr;35(2):180–86. doi:10.1111/j.1753-6405.2010.00639.x.
- de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W. Economic value of influenza vaccination. Hum Vaccin Immunother. 2012;8(1):119–29. doi:10.4161/hv.8.1.18420.
- Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine. 2008 Apr 16;26(17):2142–53. doi:10.1016/j.vaccine.2008.01.050.
- Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tsolova S, Brown C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine. 2018 Jan 25;36(4):442–52. doi:10.1016/j.vaccine.2017.12.019.
- Luz PM, Johnson RE, Brown HE. Workplace availability, risk group and perceived barriers predictive of 2016-17 influenza vaccine uptake in the United States: a cross-sectional study. Vaccine. 2017 Oct 13;35(43):5890–96. doi:10.1016/j.vaccine.2017.08.078.
- Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL, Cunningham AL. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016 Dec 20;34(52):6681–90. doi:10.1016/j.vaccine.2016.11.015.
- Zimmerman RK. Lowering the age for routine influenza vaccination to 50 years: AAFP leads the nation in influenza vaccine policy. **Am Fam Physician. 1999;60:2061–70.
- Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018–19 influenza season. MMWR Recomm Rep. 2018 Aug 24;67(3):1–20. doi:10.15585/mmwr.rr6703a1.
- Official journal of the European Union COUNCIL RECOMMENDATION of 22 December 2009 on seasonal influenza vaccination. [accessed 2020 Jan 14]. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF.
- European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons 2007–2008 to 2014–2015. [accessed 2020 Jan 14]. https://ecdc.europa.eu/sites/portal/files/documents/influenza-vaccination-2007%E2%80%932008-to-2014%E2%80%932015.pdf.
- Italian ministry of health. Prevention and control of influenza: recommendation for season 2018-2019. [accessed 2020 Jan 14]. http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2018&codLeg=64381&parte=1%20&serie=null.
- Italian ministry of health. Prevention and control of influenza: recommendation for season 2020-2021. [accessed 2020 Jun 5]. http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4859.
- Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother. 2017;13(7):1640–52. doi:10.1080/21645515.2017.1313375.
- Pitrelli A. Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis. J Prev Med Hyg. 2016;57:E34–E40.
- Stat I. Popolazione residente. [accessed 2020 Jan 14]. http://dati.istat.it/Index.aspx?DataSetCode=DCIS_POPRES1.
- Centers for Disease Control and Prevention. Influenza (Flu). People at High Risk of Developing Serious Flu–Related Complications. [accessed 2020 Jan 14]. https://www.cdc.gov/flu/about/disease/high_risk.htm.
- Trucchi C, Paganino C, Orsi A, Amicizia D, Tisa V, Piazza MF, Gallo D, Simonetti S, Buonopane B, Icardi G et al. Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. BMC Health Serv Res. 2019 Aug 19;19(1):585. doi:10.1186/s12913-019-4412-7.
- Istituto Superiore di Sanità. Influnet. Sorveglianza epidemiologica. [accessed 2020 Jan 14]. http://old.iss.it/flue/index.php?lang=1&anno=2019&tipo=13.
- Ansaldi F, Orsi A, Altomonte F, Bertone G, Parodi V, Carloni R, Moscatelli P, Pasero E, Comaschi M, Oreste P. Syndrome surveillance and molecular epidemiology for early detection and tracing of an outbreak of measles in Liguria, Italy. J Med Virol. 2009;81:1807–13. doi:10.1002/jmv.21584.
- Ansaldi F, Orsi A, Altomonte F, Bertone G, Parodi V, Carloni R, Moscatelli P, Pasero E, Oreste P, Icardi G. Emergency department syndromic surveillance system for early detection of 5 syndromes: a pilot project in a reference teaching hospital in Genoa, Italy. J Prev Med Hyg. 2008;49:131–35.
- Delibera Giunta Regionale n. 802, 5/10/2018, Gazzetta Ufficiale della Repubblica Italiana. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 28 Gennaio, 2013; Nomenclatore tariffario delle prestazioni aggiuntive, Accordo Collettivo Nazionale medici generici, 23 marzo 2005. [accessed 2020 Jan 14]. http://www.sisac.info/aree/www.sisac.info/resources/MEDICINA_GENERALE/ACN_testo_integrato.pdf.
- Ministero della Salute. Progetto Mattoni SSN, Pronto Soccorso e sistema 118. Proposta metodologica per la valutazione dei costi dell’emergenza. [accessed 2020 Jan 14]. http://www.mattoni.salute.gov.it/mattoni/documenti/11_Valutazione_costi dell’emergenza.pdf.
- Boccalini S, Bechini A, Innocenti M, Sartor G, Manzi F, Bonanni P, Panatto D, Lai PL, Zangrillo F, Rizzitelli E, et al. The universal influenza vaccination in children with Vaxigrip Tetra(®) in Italy: an evaluation of health technology assessment. J Prev Med Hyg. 2018 May 30;59(1 Suppl 1):E1–E86.
- Ministero della salute. Vaccinazione antinfluenzale in Italia: coperture vaccinali nella popolazione generale (per 100 abitanti). Stagioni 1999-2000/2018-2019. [accessed 2020 Jan 14]. http://www.salute.gov.it/imgs/C_17_tavole_19_allegati_iitemAllegati_0_fileAllegati_itemFile_3_file.pdf.
- Istituto Superiore di sanità. Epicentro. La sorveglianza Passi. I dati per l’Italia. Vaccinazione antinfluenzale. [accessed 2020 Jan 14]. http://www.epicentro.iss.it/passi/dati/VaccinazioneAntinfluenzale.asp.
- Uhart M, Bricout H, Clay E, Largeron N. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother. 2016;12:2259–68. doi:10.1080/21645515.2016.1180490.
- Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153. doi:10.1186/1741-7015-11-153.
- Allsup S, Gosney M, Haycox A, Regan M. Cost-benefit evaluation of routine influenza immunisation in people 65–74 years of age. Health Technol Assess. 2003;7:24. doi:10.3310/hta7240.
- Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics. 1999;16(Suppl. 1):63–71. doi:10.2165/00019053-199916001-00009.
- Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination: assessment for The Netherlands. Pharmacoeconomics. 1999;16(Suppl. 1):33–40. doi:10.2165/00019053-199916001-00005.
- Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost effectiveness study on influenza prevention in Hong Kong. Health Policy (New York). 2001;56(3):215–34. doi:10.1016/S0168-8510(00)00140-8.
- Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M. magnan S, Drake M. **N Engl J Med. 1995;333:889–93.
- Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine. 2003;21(17–18):2207–17. doi:10.1016/S0264-410X(03)00029-X.
- Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011 Sep-Oct;14(6):800–11. doi:10.1016/j.jval.2011.03.005.
- Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284(13):1655–63. doi:10.1001/jama.284.13.1655.
- Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006 Jul;31(1):72–79. doi:10.1016/j.amepre.2006.03.008.
- Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health. 2007 Mar-Apr;10(2):98–116. doi:10.1111/j.1524-4733.2006.00157.x.
- Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006 Feb 13;24(7):1035–43. doi:10.1016/j.vaccine.2004.12.033.
- Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine. 2010 Nov 10;28(48):7620–25. doi:10.1016/j.vaccine.2010.09.053.
- Baguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015 Oct;13(13):236. doi:10.1186/s12916-015-0452-y.
- European Centre for Disease Prevention and Control. Vaccine scheduler. Influenza recommended vaccinations. [accessed 2020 Jan 14]. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=−1.
- Calendario Vaccinale per la Vita SItI-FIMMG-FIMP 2012. [accessed 2020 Jan 14]. http://www.societaitalianaigiene.org/site/new/images/docs/calendariovaccinale/2012/cvplv.pdf.
- Ministero della salute. Influenza. Dati coperture vaccinali. [accessed 2020 Jan 14]. http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto.
- Monto AS. Seasonal influenza and vaccination coverage. Vaccine. 2010 Sep 7;28(Suppl 4):D33–44. doi:10.1016/j.vaccine.2010.08.027.
- Jiménez-García R, Herńndez-Barrera V, Rodríguez-Rieiro C, de Andrés AL, Miguel-Diez J, Trujillo IJ, Carrasco-Garrido P. Are age-based strategies effective in increasing influenza vaccination coverage?: the Spanish experience. Hum Vaccin Immunother. 2012 Feb;8(2):228–33. doi:10.4161/hv.18433.
- Honkanen P, Läärä E, Pyhälä R, Kivelä SL, Helena Mäkelä P. Comparison of two vaccination programmes in preventing influenza-related hospitalization among the elderly during two consecutive seasons. Scand J Infect Dis. 2006;38(6–7):506–11. doi:10.1080/00365540500532894.
- Ansaldi F, Orsi A, Trucchi C, De Florentiis D, Ceravolo A, Coppelli M, Schiaffino S, Turello V, Rosselli R, Carloni R, et al. Potential effect of PCV13 introduction on emergency department accesses for lower respiratory tract infections in elderly and at risk adults. Hum Vaccin Immunother. 2015;11(1):166–71. doi:10.4161/hv.34419.
- Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res. 2004 Jul;103(1–2):3–8. doi:10.1016/j.virusres.2004.02.005.